Replies to post #26421 on Mymetics Corp (MYMX)

[bow-tie]

ova virosomes

https://pubmed.ncbi.nlm.nih.gov/15652665/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162382329

[Work Harder]

Immune Design

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287331/

[Work Harder]

Founders Steven Reed

https://www.crunchbase.com/organization/immune-design

[Work Harder]

Feb 21, 2013 Preclinical studies in non-human primates already generated extremely promising data demonstrating 100% protection against multiple intra-vaginal challenges with a live virus."

Providing Mymetics obtains additional sources of financing for this project, the company plans to test its prophylactic HIV-1 vaccine candidate in a combined Phase I and II trial to investigate an additional HIV-1 antigen and a further optimized vaccine formulation.

https://finance.yahoo.com/news/data-published-plos-one-show-073000012.html?fr=sycsrp_catchall

Pending this data, a combined Phase I/II on women and men might start by 2022.

https://www.otcmarkets.com/filing/html?id=14842380&guid=wYWwk621Ej5cdth

Pending this data, a combined Phase I/II on women and men might start by 2021

https://www.otcmarkets.com/filing/html?id=14041707&guid=wYWwk621Ej5cdth

We are eagerly awaiting the results of our NIH-funded project

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167129437

They are clearly working on Hiv

& Intl says bye

LOL

[Work Harder]

Immune Design Corp Cancer antigens

The individual ID-VP02 genome

Delivery can be achieved by contacting the dendritic cells with a virosome ex vivo, whereupon the infected dendritic cells are provided to the patient. At other times, delivery may be achieved by delivering the virus to the subject in order to infect dendritic cells in vivo. The dendritic cells then stimulate antigen-specific T cells or B cells in the patient to induce cellular and humoral immune responses to the expressed antigen. In this manner, a patient suffering from a disease or disorder is treated by generating immune cells with the desired specificity.

https://patents.google.com/patent/CN104583231B/en

Merck owns that now